The company has recently received positive data from the first
feasibility trial of Prima System in age-related macular degeneration
patients – most of the patients could identify letters and some
sequences of letters.
One year after the Prima device was implanted, all five patients in the Paris-based Prima-FS trial
had light perception in the central retinal area, none had had central
visual activity at enrollment, meeting the study’s primary endpoint.
Most of the patients could identify letters, and some sequences of